Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 30INDUSTRY 4UNKNOWN 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 16Thoracic 5Gynecologic 5Other solid neoplasm 2Dermatologic 2Sarcoma 1Head & Neck 1Breast 1

Conditions

Advanced Triple Negative Breast Cancer 1

Interventions

Tamoxifen 10Capecitabine 10Trastuzumab 9Docetaxel 9pyrotinib 7Exercise 7Control Groups 7Vinorelbine 6Paclitaxel 6Letrozole 6Gemcitabine 6Cyclophosphamide 6Carboplatin 6exemestane 5Indocyanine Green 5Anastrozole 5pertuzumab 4dalpiciclib 4Injections 4Fulvestrant 4Doxorubicin 4Surgical Procedures, Operative 3Standard of Care 3Radiotherapy 3Radiation 3Mammography 3Epirubicin 3Drug Therapy 3Cisplatin 3Bevacizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × apatinib × Breast × Clear all
NCT05019690 2024-09-19

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Fujian Cancer Hospital

Phase 1/2 Recruiting
29 enrolled
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡